{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T14:30:31Z","timestamp":1762353031131,"version":"3.41.2"},"reference-count":18,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2021,3,2]],"date-time":"2021-03-02T00:00:00Z","timestamp":1614643200000},"content-version":"vor","delay-in-days":2,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,2,28]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Capecitabine is a pyrimidine antimetabolite that inhibits thymidylate synthase and is commonly used in the treatment of colorectal cancer. Adverse cardiac side effects are reported in 1\u201318% of patients receiving Capecitabine. The most commonly proposed mechanism of cardiotoxicity in the setting of Capecitabine use is vasospasm of the coronary arteries. However, cardiotoxicity can also present as an acute coronary syndrome, arrhythmia, hypertension, and\/or sudden cardiac death. Profound non-vasospastic cardiotoxicity is rare.<\/jats:p><\/jats:sec><jats:sec><jats:title>Case summary<\/jats:title><jats:p>We describe two cases of acute heart failure leading to cardiogenic shock in patients shortly after exposure to Capecitabine. Both patients did not demonstrate the characteristic transient ST elevation seen in patients with coronary artery vasospasms secondary to Capecitabine. Both patients required admission to the Acute Cardiac Care Unit requiring vasopressor and inotropic support. Thorough diagnostic investigations including echocardiography, cardiac magnetic resonance imaging, and cardiac computed tomography did not identify infarction, myocarditis, or any infiltrative process to explain their symptoms. Both patients had complete resolution of cardiac function, with no long-term sequalae.<\/jats:p><\/jats:sec><jats:sec><jats:title>Discussion<\/jats:title><jats:p>In patients receiving Capecitabine, reversible heart failure leading to cardiogenic shock should be considered as a potential cardiotoxic side effect.<\/jats:p><\/jats:sec>","DOI":"10.1093\/ehjcr\/ytab079","type":"journal-article","created":{"date-parts":[[2021,3,7]],"date-time":"2021-03-07T00:57:36Z","timestamp":1615078656000},"source":"Crossref","is-referenced-by-count":7,"title":["Capecitabine-mediated heart failure in colorectal cancer: a case series"],"prefix":"10.1093","volume":"5","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7562-6687","authenticated-orcid":false,"given":"Erin N","family":"McAndrew","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, Manitoba, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3639-9047","authenticated-orcid":false,"given":"Davinder S","family":"Jassal","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, Manitoba, Canada"},{"name":"Institute of Cardiovascular Sciences, St. Boniface Hospital, University of Manitoba, Winnipeg, Manitoba, Canada"},{"name":"Section of Cardiology, Department of Internal Medicine, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, Manitoba, Canada"},{"name":"Department of Radiology, St. Boniface Hospital, University of Manitoba, Winnipeg, Manitoba, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9393-6438","authenticated-orcid":false,"given":"Benjamin A","family":"Goldenberg","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, Manitoba, Canada"},{"name":"Section of Medical Oncology and Haematology, Department of Internal Medicine, Rady Faculty of Health Sciences, University of Manitoba, 409 Tache Ave, Winnipeg, Manitoba R2H 2A6, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christina A","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, Manitoba, Canada"},{"name":"Section of Medical Oncology and Haematology, Department of Internal Medicine, Rady Faculty of Health Sciences, University of Manitoba, 409 Tache Ave, Winnipeg, Manitoba R2H 2A6, Canada"},{"name":"Research Institute in Oncology and Hematology, Cancer Care Manitoba, Winnipeg, Manitoba, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2021,3,2]]},"reference":[{"key":"2021030700573098500_ytab079-B1","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1016\/S0959-8049(98)00058-6","article-title":"Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5 fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue","volume":"34","author":"Miwa","year":"1998","journal-title":"Eur J Cancer"},{"key":"2021030700573098500_ytab079-B2","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1016\/j.ctrv.2013.03.005","article-title":"Cardiotoxicity in cancer patients treated with 5-fluorouracil or capecitabine: a systematic review of incidence, manifestations and predisposing factors","volume":"39","author":"Polk","year":"2013","journal-title":"Cancer Treat Rev"},{"key":"2021030700573098500_ytab079-B3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11912-016-0521-1","article-title":"Fluoropyrimidine-induced cardiotoxicity: manifestations, mechanisms, and management","volume":"18","author":"Layoun","year":"2016","journal-title":"Curr Oncol Rep"},{"key":"2021030700573098500_ytab079-B4","first-page":"3028","article-title":"In vitro evidence that myocardial ischemia resulting from 5-fluorouracil chemotherapy is due to protein kinase c-mediated vasoconstriction of vascular smooth muscle","volume":"53","author":"Mosseri","year":"1993","journal-title":"Cancer Res"},{"key":"2021030700573098500_ytab079-B5","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1093\/annonc\/mdh150","article-title":"5-fluorouracil induces arterial vasocontractions","volume":"15","author":"S\u00fcdhoff","year":"2004","journal-title":"Ann Oncol"},{"key":"2021030700573098500_ytab079-B6","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1093\/annonc\/mdf108","article-title":"Incidence of cardiotoxicity with the oral fluoropyrimidine capecitabine is typical of that reported with 5-fluorouracil","volume":"13","author":"Van Cutsem","year":"2002","journal-title":"Ann Oncol"},{"key":"2021030700573098500_ytab079-B7","doi-asserted-by":"crossref","first-page":"475","DOI":"10.2165\/00003495-199957040-00003","article-title":"Cardiotoxicity of the antiproliferative compound fluorouracil","volume":"57","author":"Becker","year":"1999","journal-title":"Drugs"},{"key":"2021030700573098500_ytab079-B8","doi-asserted-by":"crossref","first-page":"5280","DOI":"10.1200\/JCO.2009.27.3953","article-title":"Fluorouracil induces myocardial ischemia with increases of plasma brain natriuretic peptide and lactic acid but without dysfunction of left ventricle","volume":"28","author":"Jensen","year":"2010","journal-title":"J Clin Oncol"},{"key":"2021030700573098500_ytab079-B9","doi-asserted-by":"crossref","first-page":"79","DOI":"10.3109\/00498254.2014.942809","article-title":"A comparison of cardiomyocyte cytotoxic mechanisms for 5-fluorouracil and its pro-drug capecitabine","volume":"45","author":"Eskandari","year":"2015","journal-title":"Xenobiotica"},{"key":"2021030700573098500_ytab079-B10","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1634\/theoncologist.2019-0762","article-title":"Fluoropyrimidine-associated cardiotoxicity: a retrospective case-control study","volume":"25","author":"Raber","year":"2020","journal-title":"Oncologist"},{"key":"2021030700573098500_ytab079-B11","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1002\/j.1875-9114.1997.tb03748.x","article-title":"Symptomatic cardiotoxicity associated with 5-fluorouracil","volume":"17","author":"Meyer","year":"1997","journal-title":"Pharmacotherapy"},{"key":"2021030700573098500_ytab079-B12","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1016\/S0140-6736(02)08514-8","article-title":"Comparison of survival, palliation, and quality of life with three chemotherapy regimens in metastatic colorectal cancer: a multicentre randomised trial","volume":"359","author":"Maughan","year":"2002","journal-title":"Lancet"},{"key":"2021030700573098500_ytab079-B13","doi-asserted-by":"crossref","first-page":"2303","DOI":"10.1016\/j.ejca.2013.03.004","article-title":"Use of raltitrexed as an alternative to 5-fluorouracil and capecitabine in cancer patients with cardiac history","volume":"49","author":"Kelly","year":"2013","journal-title":"Eur J Cancer"},{"key":"2021030700573098500_ytab079-B14","first-page":"4705","article-title":"Clinical implications of dihydropyrimidine dehydrogenase (DPD) deficiency in patients with severe 5-fluorouracil-associated toxicity: Identification of new mutations in the DPD gene","volume":"6","author":"Kuilenburg","year":"2000","journal-title":"Clin Cancer Res"},{"key":"2021030700573098500_ytab079-B15","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.jaccao.2020.04.005","article-title":"Uridine triacetate for severe fluoropyrimidine cardiotoxicity in a patient with thymidylate synthase gene variants","volume":"2","author":"Raber","year":"2020","journal-title":"JACC Cardiooncol"},{"key":"2021030700573098500_ytab079-B16","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1002\/ejhf.1292","article-title":"Activity and outcomes of a cardio-oncology service in the United Kingdom\u2014a five-year experience","volume":"20","author":"Pareek","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"2021030700573098500_ytab079-B17","doi-asserted-by":"crossref","first-page":"e322\u20137","DOI":"10.3747\/co.26.4509","article-title":"Clinical experience of patients referred to a multidisciplinary cardio-oncology clinic: an observational cohort study","volume":"26","author":"Kappel","year":"2019","journal-title":"Curr Oncol"},{"key":"2021030700573098500_ytab079-B18","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.ppedcard.2015.10.002","article-title":"Cardiotoxicity in breast cancer patients: a single center, retrospective review","volume":"39","author":"Rushton","year":"2015","journal-title":"Prog Pediatr Cardiol"}],"container-title":["European Heart Journal - Case Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ehjcr\/article-pdf\/5\/3\/ytab079\/36432448\/ytab079.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/ehjcr\/article-pdf\/5\/3\/ytab079\/36432448\/ytab079.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,31]],"date-time":"2023-10-31T06:20:12Z","timestamp":1698733212000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ehjcr\/article\/doi\/10.1093\/ehjcr\/ytab079\/6156327"}},"subtitle":[],"editor":[{"given":"Hatem","family":"Soliman Aboumarie","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]},{"given":"Domenico","family":"D'Amario","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]},{"given":"Sherif Mohammad","family":"Abd ElSamad","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]},{"given":"Bretty","family":"Sydney Bernstein","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]},{"given":"Ayse","family":"Djahit","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2021,2,28]]},"references-count":18,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,2,28]]}},"URL":"https:\/\/doi.org\/10.1093\/ehjcr\/ytab079","relation":{},"ISSN":["2514-2119"],"issn-type":[{"type":"electronic","value":"2514-2119"}],"subject":[],"published-other":{"date-parts":[[2021,3,1]]},"published":{"date-parts":[[2021,2,28]]},"article-number":"ytab079"}}